Literature DB >> 7605424

Assessment of the validity of the INR system for patients with liver impairment.

M J Kovacs1, A Wong, K MacKinnon, K Weir, M Keeney, E Boyle, M Cruickshank.   

Abstract

The INR system was developed to standardize PT reporting in patients on oral anticoagulants. We prospectively collected blood samples from 29 patients with liver impairment (INR 1.5-3.5). Control patients were on warfarin (n = 31). PT's were measured on an ACL-300 with three thromboplastin reagents. INR's were calculated using instrument specific ISI's. Other tests performed were FDP's, fibrinogen, aPTT, factors II, V, VII and X. The INR's for each patient in the study population using the three thromboplastin reagents were significantly different (p = 0.0001). Those for the control population were not (p = 0.0658). Fibrinogen, factors V, II and X were different at the 5% level of significance between the populations. FDP's were detected in 17 study subjects. The INR system is not valid for comparison of patients with liver impairment because different reagents do not give the same INR for the same sample. It is, however, no less valid than the use of PT with different thromboplastin reagents. Further study is recommended.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7605424

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  15 in total

1.  The validity of the INR system for patients with liver disease.

Authors:  Armando Tripodi
Journal:  J Thromb Thrombolysis       Date:  2011-02       Impact factor: 2.300

2.  Monitoring anticoagulation in patients with an unreliable prothrombin time/international normalized ratio: factor II versus chromogenic factor X testing.

Authors:  Lisa M Baumann Kreuziger; Yvonne H Datta; Andrew D Johnson; Nicole D Zantek; Ryan Shanley; Mark T Reding
Journal:  Blood Coagul Fibrinolysis       Date:  2014-04       Impact factor: 1.276

3.  Severe prolongation of the INR in spur cell anemia of cirrhosis: true-true and related?

Authors:  Vinay Sundaram; Abdullah M S Al-Osaimi; Jason J Lewis; Ton Lisman; Stephen H Caldwell
Journal:  Dig Dis Sci       Date:  2006-07       Impact factor: 3.199

Review 4.  Portal vein thrombosis in liver cirrhosis.

Authors:  Nao Kinjo; Hirofumi Kawanaka; Tomohiko Akahoshi; Yoshihiro Matsumoto; Masahiro Kamori; Yoshihiro Nagao; Naotaka Hashimoto; Hideo Uehara; Morimasa Tomikawa; Ken Shirabe; Yoshihiko Maehara
Journal:  World J Hepatol       Date:  2014-02-27

5.  A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation.

Authors:  Michael D Leise; W Ray Kim; Walter K Kremers; Joseph J Larson; Joanne T Benson; Terry M Therneau
Journal:  Gastroenterology       Date:  2011-02-18       Impact factor: 22.682

6.  Alterations in homeostasis after open surgery. A prospective randomized study.

Authors:  T Dedej; E Lamaj; N Marku; V Ostreni; S Bilali
Journal:  G Chir       Date:  2013 Jul-Aug

7.  Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt.

Authors:  B Angermayr; M Cejna; F Karnel; M Gschwantler; F Koenig; J Pidlich; H Mendel; L Pichler; M Wichlas; A Kreil; M Schmid; A Ferlitsch; E Lipinski; H Brunner; J Lammer; P Ferenci; A Gangl; M Peck-Radosavljevic
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

8.  Comparison of modes of prothrombin time reporting in patients with advanced liver disease associated with viral hepatitis.

Authors:  YuXiang Wei; DeHua Zheng; Li Xiao; BingYi Shi
Journal:  J Thromb Thrombolysis       Date:  2009-03-28       Impact factor: 2.300

Review 9.  Important predictor of mortality in patients with end-stage liver disease.

Authors:  Hyung Joon Kim; Hyun Woong Lee
Journal:  Clin Mol Hepatol       Date:  2013-06-27

10.  Management of anticoagulation for portal vein thrombosis in individuals with cirrhosis: a systematic review.

Authors:  Geneviève Huard; Marc Bilodeau
Journal:  Int J Hepatol       Date:  2012-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.